1. Home
  2. Medicine

Medicine

Doctors turn to Apple’s Vision Pro headset to practice surgery amid cadaver shortage

Veyond Metaverse aims to mimic the traditional cadaver experience in visceral detail with Apple’s mixed reality device.

Veyond Metaverse, a medical technology company, recently announced that its medical telepresence platform would expand its footprint to the Apple Vision Pro. 

The company’s real-time translation and remote communication services were previously used on traditional virtual and augmented reality headsets to conduct what it claims to be the world’s first “digital surgery” in 2023.

With the addition of Apple’s recently released Vision Pro headset, Veyond Metaverse appears to be entering the high-end medical telepresence market at a time when the need for new doctors exceeds the global cadaver supply.

Read more

Ripple’s Planned Stablecoin Is an ‘Unregistered Crypto Asset,’ According to SEC

ChatGPT passes neurology exam for first time

LLM 4.0 from OpenAI answered 85% of the American Board of Psychiatry and Neurology's questions correctly, implying potentially "significant" future uses for the technology.

OpenAI's latest update of its large language model (LLM), ChatGPT 4.0, has passed a clinical neurology exam with 85% correct answers in a proof-of-concept study. The research authors believe that after some fine-tuning, LLMs could have "significant applications" in clinical neurology. 

The results of the experiment, conducted by a group of researchers from the University Hospital Heidelberg and the German Cancer Research Center in Heidelberg, were published on Dec. 7. The test, performed on May 31, featured two LLMs, ChatGPT 3.5 and its later version, ChatGPT 4.0.

The researchers used the bank of questions for a neurology exam from the American Board of Psychiatry and Neurology with a small cohort of questions from the European Board for Neurology.

Read more

Ripple’s Planned Stablecoin Is an ‘Unregistered Crypto Asset,’ According to SEC

AstraZeneca partners with AI company to find cure for cancer

The collaboration aims to create a zero-shot generative AI model, which would work on creating new antibody therapeutics and enhancing the existing ones.

The pharmaceutical company that developed one of the vaccines for COVID-19, AstraZeneca, will partner with a United States-based Artificial Intelligence (AI) biologics firm, Absci, to design an antibody for cancer. 

According to a Financial Times report on Dec.

Related: AI in healthcare. New tech in diagnosis and patient care

Absci’s website claims its AI screens “billions of cells” each week, going from antibodies to wet “lab-validated candidates” in six weeks.

“AI is enabling us to not only increase the success and speed of our biologics discovery process, but also enhance the diversity of the biologics we discover.”

Absci CEO Sean McClain had also publicly confirmed the partnership, stating that AstraZeneca will help to leverage its AI work, according to a Reuters report.

AI is gaining momentum in the healthcare industry, as it could significantly accelerate both innovative research and the accuracy of data analysis. In November, Hong Kong’s Hospital Authority revealed the launch of an AI pilot to combat multidrug-resistant organisms or superbugs.

Read more

Ripple’s Planned Stablecoin Is an ‘Unregistered Crypto Asset,’ According to SEC

How blockchain improves daily healthcare routine, explained

Blockchain enhances daily healthcare by securing patient data, streamlining coordination and minimizing errors for efficient care delivery.

The significance of blockchain in the daily healthcare routine

Blockchain has the potential to revolutionize healthcare by preserving data integrity, fostering better teamwork, and increasing patient care — even in the face of ongoing difficulties with scale and integration.

Blockchain technology has the potential to completely transform healthcare practices.

Blockchain makes it easier to create a decentralized ledger that safely keeps patient data private and permits authorized access.

Additionally, the technology can strengthen clinical trial integrity, guaranteeing the reliability of outcomes and advancing medical research.

How can blockchain prevent the counterfeiting of drugs in the pharmaceutical supply chain?

Blockchain technology’s intrinsic transparency and immutability are vital in the fight against drug counterfeiting in the pharmaceutical supply chain. 

Blockchain follows the movement of pharmaceuticals from production to distribution, providing an immutable record of every stage along the way by generating an unchangeable ledger of transactions.

Every drug batch is registered as a distinct block on the chain, holding important data, including quality certifications, shipment information and production details.

Read more

Ripple’s Planned Stablecoin Is an ‘Unregistered Crypto Asset,’ According to SEC

Hong Kong to use AI against superbugs and antibiotic overprescription

The COVID-19 pandemic brought a significant rise in broad-spectrum antibiotic prescriptions, leading to antibiotic resistance development within superbugs.

Hong Kong’s Hospital Authority (HKKA) is planning to tackle a notable rise of two superbugs, vancomycin-resistant enterococci and Candida auris, with the help of artificial intelligence (AI). 

According to a South China Morning Post report from Nov. 24, citing the HKKA, the increase in the prevalence of the multidrug-resistant organisms or “superbugs” on the island occurred due to a redistribution of resources aimed at combating the COVID-19 pandemic over the past three years. As Dr Raymond Lai, the authority’s chief infection control officer, told journalists:

“A significant number of isolation wards were allocated to Covid-19 patients, leaving fewer wards available for those infected with MDROs.”

The COVID-19 pandemic also brought a significant rise in broad-spectrum antibiotic prescriptions, leading to antibiotic resistance development within the superbugs. According to the HKKA, the antibiotic resistance rate of vancomycin-resistant enterococci rose from 0.22% in 2021 to 1.2% in 2023. Patients carrying those microorganisms increased from fewer than 40 in 2021 to around 140 by late September 2023. 

Related: Owner of Hong Kong crypto exchange OSL secures $90M investment

Discovered in Hong Kong in 2019, Candida auris has witnessed an increase in carriers, soaring from nearly 200 in 2020 to more than 300 by Oct. 31, 2023. Dr. Lai cautions that approximately 10% of individuals harboring this fungus may progress to invasive infections, presenting a mortality risk ranging from 53% to 83.3%.

To combat the problem, in January 2024, HKKA will launch an AI pilot at the Prince of Wales Hospital in Sha Tin and Princess Margaret Hospital in Kwai Chung. The AI will analyze clinical data to determine the necessity of prescribing antibiotics. It will start from a single popular type of antibiotic and then expand to eight other types and 17 public hospitals.

This isn't the first time AI has been used to combat the problem of antibiotic resistance. In May 2023, AI helped MIT and McMaster University researchers identify a new antibiotic that could kill a bacteria responsible for many drug-resistant infections, Acinetobacter baumannii.

Magazine: AI Eye. 25K traders bet on ChatGPT’s stock picks, AI sucks at dice throws, and more

Ripple’s Planned Stablecoin Is an ‘Unregistered Crypto Asset,’ According to SEC

DeSci-focused DAO community funds cancer research

VitaDAO community agreed to fund an early-stage cancer research through the launch of a biotech company named Matrix Biosciences.

VitaDAO, a decentralized collective dedicated to early-stage longevity research, funded the launch of a biotech company, Matrix Biosciences, dedicated to the treatment of cancer and aging diseases.

The initial discussions around the use of high molecular weight hyaluronic acid (HMW-HA) for anti-cancer and pro-longevity effects started off in November 2022 and gained majority consensus in March 2023. The proposal snapshot reveals that 35 members cast their votes using VITA tokens.

The VITA token holders voted to agree or disagree with VitaDAO funding the HMW-HA cancer research venture. Source: snapshot.org

Out of the lot, 30 members supported the cause, 4 members abstained from voting, and 1 voted against the proposal. As an active contributor in decentralized science (DeSci), VitaDAO made an initial investment of $300,000 and plans to carry out further funding through tokenization of intellectual property (IP) in early 2024.

The HWA-HA compound is derived from the tissues of naked mole rats, a type of rodent that possess stronger cancer resistance which is responsible for their higher lifespan.

Speaking to Cointelegraph, a VitaDAO spokesperson revealed that the funds have been provided to Matrix Bio by converting USD Coin (USDC) stablecoins from the community treasury to the US dollar and wired to their bank account.

Related: 9 promising blockchain use cases in healthcare industry

Once the first batch of experiments is complete, Matrix Bio will have the option to raise additional funding by issuing IP Tokens (IPTs) in return for sharing governance rights in the ongoing development of the IP. The next round of fundraising will commence after the budget for the next phase of development is established, expected in Q1 2024.

VitaDAO believes modulating HMW-HA appears to be a viable therapeutic candidate in supporting the treatment of a complex disease like cancer. The DAO told Cointelegraph:

“Like most early-stage research, it is too early to know what the outcome of the research will provide. VitaDAO believes there is a high likelihood that the research will be translatable to the clinic.”

While the DAO’s commitment to funding this particular cancer research will depend on the results obtained from the various experiments, VitaDAO’s community treasury has in the past funded up to $1 million of a research project’s needs before enlisting the support of professional investors and pharma stakeholders.

Magazine: Beyond crypto: Zero-knowledge proofs show potential from voting to finance

Ripple’s Planned Stablecoin Is an ‘Unregistered Crypto Asset,’ According to SEC

Sam Bankman-Fried will ‘return to his depression’ without access to medication, say defense lawyers

According to Sam Bankman-Fried's legal team, he was "only able to bring a small supply” of ADHD medication and antidepressants to jail following the judge revoking his bail.

The legal team defending Sam Bankman-Fried (SBF) against criminal charges has requested a federal judge allow the former FTX CEO to have access to antidepressants while in jail.

In an Aug. 14 court filing, Bankman-Fried’s lawyers provided Judge Lewis Kaplan a proposed order which, if approved, would allow the 31-year-old to apply a transdermal patch with medication during his time behind bars. According to a letter provided by Dr. George Lerner, SBF has been under psychiatric care since February 2019 and “has a history of Major Depressive Disorder and Attention Deficit Hyperactivity Disorder (ADHD)”.

According to Dr. Lerner, SBF has been prescribed the antidepressant selegiline under the brand name Emsam to treat depression and Adderall for his ADHD. Lawyers have requested Kaplan ensure the Metropolitan Detention Center in Brooklyn have the medications stocked for the duration of Bankman-Fried’s stay in jail, as “he was only able to bring a small supply of the above-described medications” following the judge revoking his bail on Aug. 11.

“Without the aforementioned psychiatric medications [...] Mr. Bankman-Fried will experience a return of his depression and ADHD symptoms and will be severely negatively impacted in his ability to assist in his own defense,” said Dr. Lerner.

Related: Sam Bankman-Fried spends 3rd night in notorious New York jail

Lawyers who represented Bankman-Fried during his initial arrest in the Bahamas in December 2022 reported similar medical requirements, saying at the time SBF hadn’t been taking certain medication while in jail. Following extradition to the United States, Bankman-Fried was released on a $250-million bond and likely had access to medical care while largely confined to his parents’ California home.

Bankman-Fried had been free on bail for 235 days before Kaplan remanded him to custody on Aug. 11, citing concerns about alleged attempts to intimidate or influence witnesses in his criminal case. He faces 12 counts related to fraud at FTX, which will be spread across two trials scheduled to begin in October 2023 and March 2024.

Magazine: SBF ordered to jail, Bitcoin ETF delayed and SEC to appeal Ripple case: Hodler’s Digest, Aug. 6-12

Ripple’s Planned Stablecoin Is an ‘Unregistered Crypto Asset,’ According to SEC

AI tool revolutionizes brain tumor treatment by guiding surgeons: Study

Although the tool's accuracy may not match current genetic tests, it has the ability to predict a tumor's profile swiftly.

An artificial intelligence (AI) tool has emerged to assist doctors in combating aggressive brain tumors. It aids in identifying crucial characteristics that provide guidance during surgery.

The Cryosection Histopathology Assessment and Review Machine (CHARM) is an advanced tool that efficiently analyzes images to identify the genetic profile of gliomas, a type of aggressive brain tumor. Currently, this process takes days or weeks. Kun-Hsing Yu, the senior author of a July 7 report in Med, explained that surgeons rely on detailed diagnoses to guide their operations.

Although the tool's accuracy may not match current genetic tests, it has the ability to predict a tumor's profile swiftly. This quick analysis enables doctors to proceed with appropriate treatment without the need for scheduling and performing additional surgeries, saving valuable time, as explained by Yu.

In addition, CHARM can distinguish between malignant and benign tumor cells and determine the tumor's grade, indicating its level of aggressiveness. These are assessments that human pathologists typically make during surgery. However, according to Yu, CHARM could eliminate the need for a 10-to-15-minute wait or the presence of a pathologist on standby during the operation.

Graphic abstract of the CHARM study.  Source: Med

Glioma, particularly the aggressive subtype known as glioblastoma, poses a significant threat, with untreated cases leading to death in less than six months. Tragically, only 17% of individuals diagnosed with glioblastoma survive beyond the second year, as reported by the American Association of Neurological Surgeons.

Yu and his team trained a machine-learning algorithm using images of brain surgery samples and validating its accuracy against patient diagnoses. CHARM showed superior performance in identifying tumor genetic profiles compared to other AI systems.

When making critical decisions about the extent of tissue removal and the potential use of drug-coated wafers in treating glioma tumors, surgeons heavily rely on the tumor's genetic profile. Unfortunately, obtaining this information is a time-consuming process at present.

Related: AI has potential to send Bitcoin price over $750K — Arthur Hayes

The research conducted by Yu and his team is contributing to a comprehensive range of initiatives that utilize AI to enhance the diagnosis and treatment of cancer. In a notable editorial published in the June edition of the Lancet Oncology, the capabilities of certain systems were underscored for their accurate identification of individuals with an elevated risk of pancreatic, lung and breast cancer.

Magazine: AI travel booking hilariously bad, 3 weird uses for ChatGPT, crypto plugins

Ripple’s Planned Stablecoin Is an ‘Unregistered Crypto Asset,’ According to SEC

Vitalik Buterin and Polygon co-founder to help send $100M toward COVID-19 research

Research into “Long COVID” and furthering medical infrastructure development will be the two main focus areas for Buterin.

Ethereum co-founder Vitalik Buterin is working with India-based crypto fund Crypto Relief and Polygon co founder Sandeep Nailwal to send $100 million towards COVID-19 research and medical infrastructure development in India.

Buterin and Nailwal will receive $90 million in USD Coin (USDC) from Crypto Relief, while Buterin will provide $10 million out of his own pocket to further the cause. The two will then help distribute the funds. 

According to a January 2022 Twitter post from Nailwal, Crypto Relief will transfer the funds to Buterin in order for the India-based crypto fund to remain in full compliance with their local laws.

The first installment went towards tackling the COVID-19 pandemic in India through “emergency humanitarian relief.”

Crypto Relief describes itself as a community-run fund which has delivered financial relief to India during the COVID-19 pandemic.

Buterin explained in a June 8 Twitter post that COVID-19 and “future pandemics” will continue to be a “large risk in the 21st century.” According to Buterin, we need a “global solution” that combines “frontier scientific innovation” and “on-the-ground implementation.”

Buterin said much of the COVID-19 research will focus on COVID-19 airborne transmission by building better medical equipment.

“This includes improving ventilation, HEPA filtering, and experimental tech like UVC irradiation,” he said.

The other main research area will focus on “Long COVID,” Buterin added.

“The most salient risks from Covid today are the very high number of people experiencing very-long-term symptoms (aka #LongCovid), and so Long Covid research continues to be a primary focus.”

Additionally, Buterin explained that the $100 million will be disbursed to a Gnosis Safe wallet using the following contract address.

Related: The virus killer: How blockchain contributes to the fight against COVID-19

The first $100 million donation was deployed by Buterin in late January 2022 or soon after, which initially came in the form of Shiba Inu (SHIB).

It isn’t the first philanthropic effort of Buterin’s either.

In April 2022, Buterin sent $5 million worth of Ether (ETH) donations to “Aid for Ukraine” to assist its defence against Russia’s invasion in February 2022.

As of November 26, Crypto Relief has managed to raise $473 million in funds, according to the firm’s website.

Cointelegraph reached out to Crypto Relief to get a more up-to-date figure but did not receive an immediate response.

Magazine: Joe Lubin — The truth about ETH founders split and ‘Crypto Google’

Ripple’s Planned Stablecoin Is an ‘Unregistered Crypto Asset,’ According to SEC

Keith Comito on the benefits of blockchain tech and decentralization in longevity research

The co-founder of Lifespan.io is harnessing the power of decentralization to support cutting-edge scientific and technological discoveries.

Lifespan.io President and co-founder Keith Comito was into longevity before longevity was cool.

“We started our nonprofit back in 2014,” Comito said. “Back then, few credible researchers would be caught dead saying they were working on aging. It was still kind of a scientific backwater. So, we wanted to emulate what the cancer research advocates did, starting in the ‘40s.”

He said those early advocates identified the most credible research at the time and used “old-school” fundraising approaches like telethons to crowdfund for their work. They built a grassroots movement and grew their scientific expertise. Through their efforts, defeating cancer is now an international priority with communities of millions of people crusading in the fight against this devastating disease that is closely linked to aging.

Comito said Lifespan.io is taking a similar approach but for all aging-related diseases. They’ve built a large community of people by sharing verified news about breaking developments in longevity, crowdfunding research using blockchain technology, and creating some of “the most successful YouTube collaborations in the space.”

“In 2017, I helped write the scripts for a popular series of aging videos that were the highest-viewed videos the week they came out, with 14 million views within days. That was huge to hit those numbers six years ago, and the like ratio was overwhelmingly positive.” This illustrated to the field, Keith said, that it was okay for longevity researchers to come out into the open and not be ashamed of their revolutionary and life-saving work.

Comito leverages various skills honed from a diverse background, including computer programming, biology,  and mathematics. He has invented several metaverse-adjacent technologies, developed software that has been adopted in widely-used services like HBO Now, MLB at Bat and Disney+, and even accidentally created a top-charting Chuck Norris Joke Generator as a joke back in the early days of mobile applications. Today, he’s looking at ways to bring our world into the metaverse that not only excite us but also heal our minds and bodies as well. Keith sees the future of Web3 overlapping and supporting the future of longevity while tying in other hot sectors like gaming and VR.

Shaking up science

Comito said that one area he’s spent the last few years exploring is the pure fundraising capabilities of cryptocurrency, working with organizations such as Gitcoin and Angel Protocol to brainstorm new models of crypto philanthropy to fund scientific breakthroughs. Of course, a number of “crypto heavyweights are already supporting life extension research,” he says. Vitalik Buterin, for example, has supported several longevity projects, donating crypto to causes like the SENS Research Foundation. This connection goes all the way back to the birth of cryptocurrency - through the support of early cypherpunks like Hal Finney, says Comito, who theorizes the common thread is transcending boundaries, whether financial or biological, to lead humanity to a brighter future.

The potential of blockchain technology to drive longevity research goes far beyond raising money, particularly with respect to decentralized science, or “DeSci.” “There are promising potential treatments for Alzheimer’s which lack traditional profit motives, for example, ones that can be developed with blockchain-based crowdsourcing,” he said.

Therapies like flickering lights and sounds at certain frequencies could remediate dementia. Comito himself is working on such an approach with his colleagues at Lifespan.io - aiming to launch a first-in-kind decentralized clinical trial to test non-drug interventions for Alzheimer’s disease, with the blessing of government organizations like the National Institute of Health.

“There have been very public failures on the treatment of Alzheimer’s with traditional approaches,” Comito said. “Over a trillion dollars has been spent on research, with strikingly little progress.”

He said a non-drug solution discovered by a decentralized group of people on the internet would be a “complete earthquake.” Decentralized science, powered by groups like decentralized autonomous organizations (DAOs), can also overcome issues associated with traditional research institutes. DAO governance promotes transparency and rewards productivity, aspects which can be instrumental in advancing longevity research.

“I think we tend to view organizations like the FDA and the NIH as being calcified and anti-crypto,” Comito said. “But my experience has been that leaders of such organizations actually want us to shake things up. With the help of blockchain technology, we can achieve medical advances so powerful and undeniable that existing systems will have no choice but to change.”

Crypto will power further innovation in the space

Comito acknowledges that crypto has some perception issues to overcome in the wake of the FTX collapse. However, he sees that as more of a product of the overall market. While it is true that it’s hard right now for charities to raise money, Comito is optimistic that we will see a future filled with exponential growth.

“Last year, a number of charities started dipping into crypto because the market was hot,” he said. “They’ve drunk the Kool-Aid, and now’s the time to build and find out who’s truly getting something interesting done. When the market recovers, these projects will be in great shape. We’re building tools to do something amazing in the next several years.”

Organizations like Endaoment and The Giving Block are laying the foundation for a philanthropic shift. In the longevity space, VitaDAO and the Longevity Science Foundation continue to fund cutting-edge research in the quest to help extend our lifespans and enrich our health. This could also look like crypto and blockchain technology eventually playing a role in streamlining data interactions which will have a role in facilitating longevity.

We are fast approaching a world where everyone can own their data, carrying it in their healthcare wallet. This can help eliminate bloated industry architecture that relies on paper records in so much of the world. In turn, this can accelerate opportunities for people to participate in clinical trials, reduce costs, facilitate payments to participants, limit emission-heavy travel, achieve diversity goals, and lead to more standardized data.

“Concerns have to be managed, but that is something we can do together as a crowd, which we consider a DAO of humanity,” Comito said. “Blockchain technology is not going away, and will have a key part to play in a future where all people will have sovereignty - not only over their currency and data but over their healthy lifespans as well.”

Ripple’s Planned Stablecoin Is an ‘Unregistered Crypto Asset,’ According to SEC